Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD Mutated AML Following Allogeneic Hematopoietic Cell Transplantation Liang, E. C., Chen, C., Lu, R., Mannis, G. N., Muffly, L. AMER SOC HEMATOLOGY. 2021

View details for DOI 10.1182/blood-2021-149805

View details for Web of Science ID 000736398805037